Key facts
- Akeso's cancer drug ivonescimab demonstrated superior efficacy compared to AstraZeneca's Imfinzi in a Phase 3 trial.
- The trial targeted patients with non-small cell lung cancer.
- The primary endpoint of improved progression-free survival was met.
- The results indicate a potential new treatment option for lung cancer patients.
China's Akeso has announced that its cancer drug, ivonescimab, has outperformed AstraZeneca's Imfinzi in a Phase 3 clinical trial for non-small cell lung cancer. The trial successfully met its primary endpoint, demonstrating a significant improvement in progression-free survival for patients treated with ivonescimab.
This development marks a potential advancement in the treatment landscape for lung cancer, offering a new therapeutic option that has shown greater efficacy than a currently established drug. Further details on the trial's specific metrics and patient outcomes are expected to be released.